Brief Report - Monoclonal Antibodies Illustrate the Difficulties in Measuring Blocking TSH Receptor Antibodies.
Graves’ disease
Hashimoto autoimmune thyroiditis
TSH receptor (TSHR)
thyroid bioassay
thyroid blocking antibodies
thyroid stimulating antibodies
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
05
2022
accepted:
23
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
3
8
2022
Statut:
epublish
Résumé
TSH receptor (TSHR) antibodies are the cause of Graves' disease and may also be found in patients with Hashimoto's thyroiditis. They come in at least three varieties: thyroid stimulating, thyroid blocking and neutral. The measurement of TSH receptor antibodies in Graves' disease and Hashimoto's thyroiditis is a common clinical activity and can be useful in diagnosis and prognosis. We show that it is not possible to detect the blocking variety of TSHR antibody in patients with Graves' disease because the stimulating antibody may overwhelm the measurement of blocking in the bioassays available for their measurement and may blind the valid interpretation of the results. To help explain this in more detail we show a series of studies with monoclonal TSHR antibodies which support this conclusion.
Identifiants
pubmed: 35909553
doi: 10.3389/fendo.2022.943459
pmc: PMC9335193
doi:
Substances chimiques
Antibodies, Monoclonal
0
Autoantibodies
0
Receptors, Thyrotropin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
943459Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Davies, Morshed, Mezei and Latif.
Déclaration de conflit d'intérêts
TD is a Board Member of Kronus Inc, Star, ID which distributes diagnostics including for TSH receptor antibodies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Thyroid. 2010 Aug;20(8):851-6
pubmed: 20615137
Endocr J. 2005 Oct;52(5):525-9
pubmed: 16284428
Sci Signal. 2018 Jan 23;11(514):
pubmed: 29363585
J Clin Invest. 2002 Dec;110(11):1667-74
pubmed: 12464672
J Clin Endocrinol Metab. 2016 May;101(5):1998-2004
pubmed: 26964732
Horm Metab Res. 2015 Sep;47(10):727-34
pubmed: 26361259
Nat Rev Dis Primers. 2020 Jul 2;6(1):52
pubmed: 32616746
Thyroid. 2004 Aug;14(8):560-70
pubmed: 15320966
Thyroid. 1992 Spring;2(1):27-30
pubmed: 1356052
J Clin Endocrinol Metab. 1966 May;26(5):518-26
pubmed: 5938367
J Autoimmun. 2013 Dec;47:17-24
pubmed: 23958398
J Clin Endocrinol Metab. 1974 Nov;39(5):826-32
pubmed: 4425101
Thyroid. 2008 Jul;18(7):735-46
pubmed: 18631002
Horm Metab Res. 2018 Dec;50(12):853-862
pubmed: 30286485
Thyroid. 2013 Jan;23(1):14-24
pubmed: 23025526
Front Endocrinol (Lausanne). 2016 Jan 28;7:3
pubmed: 26858688
N Z Med J. 1975 Jan 8;81(531):22-3
pubmed: 1055310
J Endocrinol. 1977 Dec;75(3):401-7
pubmed: 201719
J Clin Endocrinol Metab. 2018 Oct 1;103(10):3668-3677
pubmed: 30099546
Clin Dev Immunol. 2005 Jun;12(2):137-43
pubmed: 16050145